Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 9 July

Jessica Amir
July 9, 2021

Morning Bell 9 July

Paulina Peters
July 9, 2021

Morning Bell 8 July

Jessica Amir
July 8, 2021

Morning Bell 7 July

Sophia Mavridis
July 7, 2021

Morning Bell 6 July

Jessica Amir
July 6, 2021

Morning Bell 5 July

Jessica Amir
July 5, 2021

Weekly Wrap 2 July

Jessica Amir
July 2, 2021

Morning Bell 2 July

Sophia Mavridis
July 2, 2021

Morning Bell 1 July

Paulina Peters
July 1, 2021

Morning Bell 30 June

Jessica Amir
June 30, 2021

Morning Bell 29 June

Jessica Amir
June 29, 2021

Morning Bell 28 June

Jessica Amir
June 28, 2021